Bard books positive Q4

C. R. Bard has reported a rise in net income for its unaudited financial results of its 2008 fourth quarter, which ended Dec. 31, 2008.

Net income for the quarter was $149.4 million, compared to $105.2 million in the same quarter last year. For the full year 2008, net income was $416.5 million, compared to full year 2007 results of $406.4 million.

For the quarter, net sales were $634.2 million, an increase of 9 percent over the prior-year period earning of $583.3 million. In the United States, net sales were $436.3 million and net sales outside the U.S. were $197.9 million, compared to the prior-year periods, according to the Murray Hill, N.J.-based Bard.

Within its product groups, its vascular segment saw higher sales in the fourth quarter, reaching $168.5 million, compared to $141.9 million in the same period last year.

Meanwhile, its surgical specialties group saw a slight downtick in sale, booking $95.5 million in the 2008 fourth quarter compared to $96.5 million last year, according to the company.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.